Medicus Pharma’s Phase 2 SkinJect Trial Receives Positive Clinical Validation
An independent review validated Medicus Pharma’s Phase 2 SkinJect study for non-melanoma skin cancer as clinically relevant, reinforcing its mechanism and safety profile. The evaluation supports expansion into larger patient cohorts and accelerates planning for pivotal trials in the company’s oncology pipeline.
1. Independent assessment confirms clinical relevance
Medicus Pharma engaged an external evaluation team to review data from its Phase 2 SkinJect trial targeting non-melanoma skin cancer. The assessment concluded that the study met its clinical relevance thresholds, highlighting consistent treatment effects and a favorable safety profile.
2. Implications for development roadmap
With the positive clinical validation, Medicus Pharma plans to expand patient enrollment and initiate discussions for Phase 3 trial design. This milestone strengthens its oncology pipeline, potentially enhancing partner interest and future funding opportunities.